Eplerenone

Drug Profile

Eplerenone

Alternative Names: CGP 30083; Epoxymexrenone; Inspra; SC 66110; Selara

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Medical University of Graz; Pfizer; Solvotrin Innovations
  • Class Antihypertensives; Heart failure therapies; Lactones; Pregnenes; Small molecules
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Phase III Chronic heart failure
  • Phase II Left ventricular dysfunction
  • No development reported Postmyocardial infarction; Primary hyperparathyroidism

Most Recent Events

  • 25 Jan 2018 No development reported - Phase-III for Primary hyperparathyroidism in Austria (PO)
  • 01 Nov 2016 Pfizer terminates a phase II/III trial due to futility for Heart failure in Canada (PO) (NCT01708798)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top